{
    "nctId": "NCT00770354",
    "briefTitle": "Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer",
    "officialTitle": "A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "The primary efficacy endpoint is overall response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic breast cancer not amenable to curative therapy\n* Measurable disease according to the RECIST criteria\n* Documented estrogen receptor-positive and/or progesterone receptor-positive tumour\n* Postmenopausal women\n\nExclusion Criteria:\n\n* Prior chemotherapy and/or endocrine therapy for advanced breast disease\n* Relapse within 12 months after treatment discontinuation of an aromatase inhibitor in the adjuvant setting\n* Unknown hormonal receptor status\n* Known HER2/neu-positivity",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}